Imre Noth

US Patent:

20120035067, Feb 9, 2012

Filed:

Mar 3, 2011

Appl. No.:

13/039989

Inventors:

Naftali Kaminski - Pittsburgh PA, US
Kevin F. Gibson - Gibsonia PA, US
Bernadette R. Gochuico - Potomac MD, US
Thomas J. Richards - Pittsburgh PA, US
Ivan Rosas - Pittsburgh PA, US
Kazuhisa Konishi - Kyoto, JP
Moises Selman - Mexico D.F., MX
Imre Noth - Chicago IL, US

International Classification:

C40B 30/04
C40B 40/06
C40B 40/10
G01N 33/573

US Classification:

506 9, 435 74, 506 16, 506 18

Abstract:

The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.

US Patent:

20060014698, Jan 19, 2006

Filed:

Jul 14, 2005

Appl. No.:

11/182279

Inventors:

Michael O'Connor - Wilmette IL, US
Edward Naureckas - Oak Park IL, US
Imre Noth - Chicago IL, US

International Classification:

A61K 38/05
A61K 31/737

US Classification:

514018000, 514054000

Abstract:

The present invention provides methods and pharmaceutical compositions for the treatment of bronchial disorders by inhalation therapy. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of a sulfated pentasaccharide and a peptidomemtic of a tripeptide. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of argatroban and fondaparinux.

US Patent:

20220291231, Sep 15, 2022

Filed:

Jan 13, 2020

Appl. No.:

17/422033

Inventors:

- Charlottesville VA, US
Imre Noth - Charlottesville VA, US

International Classification:

G01N 33/68

Abstract:

Provided are methods for generating prognostic signatures for subject diagnosed with Idiopathic Pulmonary Fibrosis (IPF) with respect to decline in lung Forced Vital Capacity (FVC). The methods can include determining first expression levels for one or more genes as set forth herein in a first biological sample obtained from a subject diagnosed with IPF, determining a second expression level for the same one or more genes in a second biological sample obtained from the subject, and comparing the first and second expression levels for the one or more genes to provide a prognostic signature. The first and second biological samples can include peripheral blood mononuclear cells (PBMCs) and/or nucleic acids extracted from PBMCs. Also provided are methods for classifying subjects with IPF as being at risk for FVC decline, for identifying and treating at risk subjects, and for monitoring the progress of treatments.

US Patent:

20140335547, Nov 13, 2014

Filed:

May 14, 2014

Appl. No.:

14/277194

Inventors:

- D.F. Mexico, MX
- Bethesda MD, US
- Chicago IL, US
- Pittsburgh PA, US
Ivan Rosas - Pittsburgh PA, US
Kazuhisa Konishi - Pittsburgh PA, US
Moises Selman - Coyoacan, MX
Imre Noth - Chicago IL, US

Assignee:

Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas - D.F. Mexico
United States Of America, Secretary, Dept. Of Health And Human Services - Bethesda MD
The University Of Chicago - Chicago IL
University Of Pittsburgh - Of The Commonwealth System Of Higher Education - Pittsburgh PA

International Classification:

G01N 33/573

US Classification:

435 792, 435 71

Abstract:

The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.